PMC7569524_01
Analysis of the phosphorylation of IRAK-4 and STAT-3 in B cells and Monocytes. (A,B) IRAK-4 in B cells. (C,D) IRAK-4 in monocytes. (E,F) STAT-3 in monocytes. On the left, comparison of phosphorylation levels in an untreated Schnitzler syndrome patient (SchS, male, 62 years old), rheumatoid arthritis patient (RA, male, 73 years old), and healthy control (HC, male, 62 years old, with methotrexate therapy) with percentage of cells with phosphorylated target molecules in brackets; on the right, comparison of phosphorylation levels of the SchS patient before and 6 months after initiation of anakinra. Further results of healthy controls and RA patients can be seen in the Supplementary Material.
fimmu-11-576200-g001.jpg
PMC7569524_01_fimmu-11-576200-g001.jpg
F1
We found a distinct phosphorylation of IRAK-4 in 26% of monocytes (Figure 1C) and 86% of B cells (Figure 1A) but no increase of STAT-3 (Figure 1E). Moreover, pIRAK-4 in B cells and in monocytes was reduced to a nearly normal level (Figures 1B,D), whereas STAT-3 in monocytes increased slightly from initially 0.36 to 5.49% (Figure 1F). 1.5 years after diagnosis of SchS, the patient is still on anakinra therapy without any signs of SchS.